<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145259</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00067047</org_study_id>
    <nct_id>NCT03145259</nct_id>
  </id_info>
  <brief_title>Evaluation of Bioavailability of Diclofenac Dermal Products</brief_title>
  <official_title>Evaluation of Bioavailability of Diclofenac Dermal Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will utilize already FDA-approved marketed diclofenac products in healthy adults to
      generate data for establishing rate of drug delivery comparisons between diclofenac epolamine
      patches and diclofenac sodium solution in healthy adults and to determine skin
      concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will utilize already FDA-approved marketed diclofenac products in healthy adults to
      generate data for establishing rate of drug delivery comparisons between diclofenac epolamine
      patches and diclofenac sodium solution in healthy adults and to determine skin
      concentrations. This study supports FDA's continuing effort to identify the most accurate,
      sensitive, reproducible and efficient methods to evaluate topical dermatological drug
      products.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The same 12 volunteers received all treatments in three separate study arms.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Diclofenac Concentrations</measure>
    <time_frame>blood samples obtained over 51 hour time period for study session 1 and over 47 hour time period for study session 2; through study completion</time_frame>
    <description>Study Session 1: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24, 27, 30, 32, 51 h Study Session 2: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 23, 26, 29, 31, 47 h Study Session 3: no blood samples obtained</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Diclofenac patch</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Session 2: diclofenac sodium solution (PK) [47 h study duration]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac patch and solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Epolamine Patch</intervention_name>
    <description>patch</description>
    <arm_group_label>Diclofenac patch</arm_group_label>
    <arm_group_label>Diclofenac patch and solution</arm_group_label>
    <other_name>patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac sodium solution</intervention_name>
    <description>solution</description>
    <arm_group_label>Diclofenac patch and solution</arm_group_label>
    <arm_group_label>Diclofenac solution</arm_group_label>
    <other_name>solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or non-pregnant, women who are of any ethnic background between the age of 18 to
             45 years old

          2. Subjects must be non-smokers (must have refrained from the use of nicotine-containing
             substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco,
             snuff, gum, patches or electronic cigarettes) over the previous 2 months and are not
             currently using tobacco products

          3. Provide written informed consent before initiation of any of the study procedures

          4. Agree not to participate in another clinical trial/study during the study period or to
             participate in an investigational drug study for at least 1 month after the last study
             session

          5. Able to adhere to the study protocol and study restrictions

          6. Able to participate in all study sessions

          7. Has a volar forearm of either at least 24 cm (9.45 inches) in length or of sufficient
             size that can accommodate the products to be tested in a study area that begins at
             least 5 cm (1.97 inches) above the wrist and ends a minimum of 0.5 cm (0.197 inches)
             below the antecubital fossa (i.e., the bend in the arm at the elbow).

          8. Subjects have upper arms large enough to allow for placement of two 140 cm2 [21.7 in2]
             patches (distance from acromion process of the scapula to olecranon process should be
             a minimum of 35 cm [13.8 inches]; circumference of upper arms should be a minimum of
             28 cm [11.02 inches] and 200 cm2 [31 in2] area for application of solution

          9. Subjects deemed to be healthy as judged by the Medically Accountable Investigator
             (MAI) and determined by medical history, physical examination and medication history

         10. Negative urine drug screening test (cannabinoids, amphetamines, barbiturates,
             benzodiazepine, cocaine, methadone, opiates, PCP)

         11. Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb),
             platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN),
             creatinine, alanine transaminase (ALT) and aspartate aminotransferase (AST)

         12. Have normal screening laboratories for urine protein and urine glucose

         13. Female subjects must be of non-childbearing potential (as defined as surgically
             sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more
             than 1 year), or if of childbearing potential must be non-pregnant at the time of
             enrollment and on the morning of each study session, and must agree to use hormonal or
             barrier birth control such as implants, injectables, combined oral contraceptives,
             some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner

         14. Agrees not to donate blood to a blood bank throughout participation in the study and
             for at least 3 months after last study session

         15. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave
             abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right
             bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats
             per minute)

         16. Have normal vital signs:

               -  Temperature 35-37.9°C (95-100.3°F)

               -  Systolic blood pressure 90-165 mmHg

               -  Diastolic blood pressure 60-100 mmHg

               -  Heart rate 55-100 beats per minute

               -  Respiration rate 12-20 breaths per minute

        Exclusion Criteria:

          1. Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy
             test at enrollment or positive urine pregnancy test on the morning of the first day of
             each study session

          2. Smokers (current use or use over the previous 2 months of nicotine-containing
             substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco,
             snuff, gum, patch or electronic cigarettes)

          3. Participation in any ongoing investigational drug trial/study or clinical drug
             trial/study

          4. History as either reported by the subject or evident to the Medically Accountable
             Investigator (MAI) of infectious disease or skin infection or of chronic skin disease
             (e.g., psoriasis, atopic dermatitis)

          5. History of diabetes

          6. History of significant skin cancers (e.g., melanoma, squamous cell carcinoma) except
             basal cell carcinomas that were superficial and did not involve the investigative
             sites

          7. Body Mass Index (BMI) ≥30 kg/m2

          8. History of chronic obstructive pulmonary disease or cor pulmonale, or substantially
             decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory
             depression

          9. Active positive Hepatitis B, C and/or HIV serologies

         10. Positive urine drug screening test

         11. Use of chronic prescription medications during the period 0 to 30 days; or
             over-the-counter medication (e.g. antihistamines, topical corticosteroids) and short
             term (&lt;30 days) prescription medications during the period 0-3 days before a study
             session (vitamins, herbal supplements and birth control medications not included)

         12. Currently taking daily oral nonsteroidal anti-inflammatory drug [NSAIDs] (aspirin,
             ibuprofen, naproxen, etc…)

         13. Currently taking daily anticoagulants or within the past month prior to entry into the
             study (warfarin, heparin, rivaroxaban, dabigatran, etc…), ACE-inhibitors,
             cyclosporine, diuretics, lithium or methotrexate

         14. Donation or loss of greater than one pint of blood within 60 days of entry to the
             study

         15. Any prior adverse reaction or hypersensitivity to diclofenac, aspirin, ibuprofen,
             naproxen or other nonsteroidal anti-inflammatory drug (NSAID), other inactive
             ingredients in the patch or topical solution or to adhesives or tapes used to cover or
             tape strip the treatment sites

         16. Received an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within 1 month before enrollment in this study or expects to receive an
             experimental agent during the study

         17. Eat or drink anything containing alcohol within 24 hours prior to dose administration

         18. Any condition that would, in the opinion of the Medically Accountable Investigator
             (MAI), place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol

         19. Subject has an obvious difference in skin color between arms or the presence of a skin
             condition, excessive hair at the application site (upper arms/volar forearms),
             sunburn, raised moles or scars, open sores at application site (upper arms/volar
             forearms), scar tissue, tattoo, or coloration that would interfere with placement of
             diclofenac products, skin assessment, or reactions to diclofenac

         20. History of asthma or urticaria,, hypertension, myocardial infarction, thrombotic
             events, stroke, congestive heart failure, impaired renal function or liver disease

         21. History of gastrointestinal bleeding or peptic ulcer disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra L Stinchcomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem E Hassan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Research Center (GCRC) at the University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <results_first_submitted>May 18, 2020</results_first_submitted>
  <results_first_submitted_qc>June 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2020</results_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Diclofenac hydroxyethylpyrrolidine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03145259/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac</title>
          <description>Study Session 1. diclofenac epolamine patch Study Session 2. diclofenac sodium solution Study Session 3. diclofenac epolamine patch pieces and diclofenac sodium solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac</title>
          <description>Study Session 1. diclofenac epolamine patch Study Session 2. diclofenac sodium solution Study Session 3. diclofenac epolamine patch pieces and diclofenac sodium solution</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Diclofenac Concentrations</title>
        <description>Study Session 1: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24, 27, 30, 32, 51 h Study Session 2: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 23, 26, 29, 31, 47 h Study Session 3: no blood samples obtained</description>
        <time_frame>blood samples obtained over 51 hour time period for study session 1 and over 47 hour time period for study session 2; through study completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Epolamine Patches</title>
            <description>diclofenac epolamine patches
Diclofenac Epolamine Patch: patch</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium Solution</title>
            <description>diclofenac sodium solution
diclofenac sodium solution: solution</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Diclofenac Concentrations</title>
          <description>Study Session 1: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24, 27, 30, 32, 51 h Study Session 2: within 60 min prior to dosing, 1, 2, 3, 4, 5, 6, 7, 23, 26, 29, 31, 47 h Study Session 3: no blood samples obtained</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="10.8"/>
                    <measurement group_id="O2" value="40.0" spread="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the beginning of the study (10/04/17) through when the last adverse event resolved (05/15/20) [2 years, 7 months] TDCLO-001 (431 days), TDCLO-003 (156 days), TDCLO-004 (740 days), TDCLO-010 (37 days), TDCLO-011 (162 days), TDCLO-012 (306 days), TDCLO-013 (500 days), TDCLO-016 (76 days), TDCLO-019 (52 days), TDCLO-020 (213 days), TDCLO-024 (79 days), TDCLO-029 (58 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Epolamine Patches</title>
          <description>diclofenac epolamine patches
Diclofenac Epolamine Patch: patch</description>
        </group>
        <group group_id="E2">
          <title>Diclofenac Sodium Solution</title>
          <description>diclofenac sodium solution
diclofenac sodium solution: solution</description>
        </group>
        <group group_id="E3">
          <title>Diclofenac Epolamine Patches and Diclofenac Sodium Solution</title>
          <description>patch pieces and solution
Diclofenac Epolamine Patch: patch
diclofenac sodium solution: solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>decreased blood pressure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual flow</sub_title>
                <description>light menstrual flow (participant noted different from normal)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>increased heart rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>raised skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>abrasions</sub_title>
                <description>from tape strips used for skin tape stripping</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>scabs</sub_title>
                <description>skin tape stripping sites</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin tingly sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin peeling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>upset stomach/indigestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <description>post blood draws</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin erythema (redness)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audra Stinchcomb</name_or_title>
      <organization>University of Maryland, Baltimore School of Pharmacy</organization>
      <phone>410-706-2646</phone>
      <email>astinchc@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

